文献速递白血病

米哚妥林治疗下FLT3-ITD突变急性髓系白血病的克隆演化

Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin.
PubMed 文献 · Blood · 2021-01-01

研究分析RATIFY或16-10试验中54例接受米哚妥林治疗的FLT3-ITD阳性AML患者的配对样本,采用Genescan和全外显子测序。耐药或进展时46%患者转为FLT3-ITD阴性但获得信号通路突变,11%出现耐药ITD克隆选择,32%无FLT3-ITD突变变化。

要点

  • 米哚妥林治疗耐药时近半数患者FLT3-ITD转阴并获信号通路突变。
  • 11%病例出现耐药ITD克隆选择作为潜在驱动。
  • 32%病例无FLT3-ITD变化,提示旁路耐药或药物浓度不足。

核心结论

  • 米哚妥林联合强化化疗治疗FLT3-ITD阳性AML时,耐药机制包括FLT3-ITD丢失伴信号通路突变、耐药ITD克隆选择及无FLT3-ITD变化。

研究设计与样本

  • 分析RATIFY或德国-奥地利AML研究组16-10试验中54例接受米哚妥林治疗的FLT3-ITD阳性AML患者的诊断与复发或难治配对样本,采用Genescan检测FLT3-ITD和全外显子测序。

主要发现

  • 耐药或进展时46%患者变为FLT3-ITD阴性但获得信号通路突变(如MAPK)。
  • FLT3-ITD持续存在者中11%发现耐药ITD克隆选择作为潜在驱动。
  • 32%病例未观察到FLT3-ITD突变变化。

临床怎么用

  • 对米哚妥林治疗失败的FLT3-ITD阳性AML患者,应重新评估FLT3-ITD状态及信号通路突变以指导后续治疗。

局限性

  • 样本量有限(54例配对样本),部分机制推测需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In the international randomized phase 3 RATIFY (Randomized AML Trial In FLT3 in patients less than 60 Years old) trial, the multikinase inhibitor midostaurin significantly improved overall and event-free survival in patients 18 to 59 years of age with FLT3-mutated acute myeloid leukemia (AML). However, only 59% of patients in the midostaurin arm achieved protocol-specified complete remission (CR), and almost half of patients achieving CR relapsed. To explore underlying mechanisms of resistance, we studied patterns of clonal evolution in patients with FLT3-internal tandem duplications (ITD)-positive AML who were entered in the RATIFY or German-Austrian Acute Myeloid Leukemia Study Group 16-10 trial and received treatment with midostaurin. To this end, paired samples from 54 patients obtained at time of diagnosis and at time of either relapsed or refractory disease were analyzed using conventional Genescan-based testing for FLT3-ITD and whole exome sequencing. At the time of disease resistance or progression, almost half of the patients (46%) became FLT3-ITD negative but acquired mutations in signaling pathways (eg, MAPK), thereby providing a new proliferative advantage. In cases with FLT3-ITD persistence, the selection of resistant ITD clones was found in 11% as potential drivers of disease. In 32% of cases, no FLT3-ITD mutational change was observed, suggesting either resistance mechanisms bypassing FLT3 inhibition or loss of midostaurin inhibitory activity because of inadequate drug levels. In summary, our study provides novel insights into the clonal evolution and resistance mechanisms of FLT3-ITD-mutated AML under treatment with midostaurin in combination with intensive chemotherapy.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Schmalbrock LK, Dolnik A, Cocciardi S, et al. Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin. Blood. 2021. PMID: 33598693. doi:10.1182/blood.2020007626

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。